» Articles » PMID: 21736883

Therapeutic Window of Opportunity for the Neuroprotective Effect of Valproate Versus the Competitive AMPA Receptor Antagonist NS1209 Following Status Epilepticus in Rats

Overview
Specialties Neurology
Pharmacology
Date 2011 Jul 9
PMID 21736883
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Epileptogenesis, i.e., the process leading to epilepsy, is a presumed consequence of brain insults including head trauma, stroke, infections, tumors, status epilepticus (SE), and complex febrile seizures. Typically, brain insults produce morphological and functional alterations in the hippocampal formation, including neurodegeneration in CA1, CA3, and, most consistently, the dentate hilus. Most of these alterations develop gradually, over several days, after the insult, providing a therapeutic window of opportunity for neuroprotective agents in the immediate post-injury period. We have previously reported that prolonged (four weeks) treatment with the antiepileptic drug valproate (VPA) after SE prevents hippocampal damage and most of the behavioral alterations that occur after brain insult, but not the development of spontaneously occurring seizures. These data indicated that VPA, although not preventing epilepsy, might be an effective disease-modifying treatment following brain insult. The present study was designed to (1) determine the therapeutic window for the neuroprotective effect of VPA after SE; (2) compare the efficacy of different intermittent i.p. versus continuous i.v. VPA treatment protocols; and (3) compare VPA with the glutamate (AMPA) receptor antagonist NS1209. As in our previous study with VPA, SE was induced by sustained electrical stimulation of the basolateral amygdala in rats and terminated after 4 h by diazepam. In vehicle controls, >90% of the animals developed significant neurodegeneration in the dentate hilus, whereas damage in CA1 and CA3 was more variable. Hilar parvalbumin-expressing interneurons were more sensitive to the effects of seizures than somatostatin-stained hilar interneurons or hilar mossy cells. Among the various VPA treatment protocols, continuous infusion of VPA for 24 immediately following the SE was the most effective neuroprotective treatment, preventing most of the neuronal damage. Infusion with NS1209 for 24 h exhibited similar neuroprotective efficacy. These data demonstrate that short treatment after SE with either VPA or NS1209 is powerfully neuroprotective, and may be disease-modifying treatments following brain insult.

Citing Articles

Valproic acid attenuates the severity of astrogliosis in the hippocampus of animal models of temporal lobe epilepsy.

Feng H, Luo J, Li Z, Zhao Y, Liu Y, Zhu H IBRO Neurosci Rep. 2024; 17:471-479.

PMID: 39669223 PMC: 11635005. DOI: 10.1016/j.ibneur.2024.11.003.


Antiseizure medication ≤48 hours portends better prognosis in new-onset epilepsy.

Menetre E, De Stefano P, Megevand P, Sarasin F, Vargas M, Kleinschmidt A Eur J Neurol. 2023; 31(2):e16107.

PMID: 37889889 PMC: 11236038. DOI: 10.1111/ene.16107.


Transcranial photobiomodulation add-on therapy to valproic acid for pentylenetetrazole-induced seizures in peripubertal rats.

Tsai C, Chang S, Chang H BMC Complement Med Ther. 2022; 22(1):81.

PMID: 35313886 PMC: 8935768. DOI: 10.1186/s12906-022-03562-9.


On the application of the window of opportunity and complex network to risk analysis of process plants operations during a pandemic.

Sun H, Wang H, Yang M, Reniers G J Loss Prev Process Ind. 2020; 68:104322.

PMID: 33071470 PMC: 7552987. DOI: 10.1016/j.jlp.2020.104322.


Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors.

Hanada T Biomolecules. 2020; 10(3).

PMID: 32197322 PMC: 7175173. DOI: 10.3390/biom10030464.